Note: Ingredients listed on restricted chemical lists
EC/CAS
10117-38-1
Name of the chemical
Potassium sulphite
Concentration
N/A
EC/CAS
111-46-6
Name of the chemical
diethyleneglycol
Concentration
N/A
EC/CAS
123-31-9
Name of the chemical
1,4-Dihydroxybenzol (790/2009)
Concentration
N/A
General Information
Revision date
2004-03-11
Product name
GP Developer Working Strength
Product Synonyms
Aqueous Photochemical Mixture
Chemical name
GP Developer Working Strength
Emergency telephone
(303) 623-5716
Icons in SDS
Company Information
company name
AGFA CORPORATION
GHS Information
Signal word
WARNING!
Section 2
SECTION 2: Hazards identification
This product as a whole has not been tested. This hazard information is for the individual ingredients. ***************************************************************** * EMERGENCY OVERVIEW * WARNING! Color Light Yellow; Form Liquid; Clear; Odor * * Odorless; Causes respiratory tract irritation; May cause * * allergic respiratory reaction; Causes skin irritation; May * * cause allergic skin reaction; Causes eye irritation; * * Irritating gases/fumes may be given off during burning or * * thermal decomposition. * *****************************************************************
Potential health effects
ROUTES OF ENTRY..................: Eye and skin contact, inhalation of vapors or mists, accidental ingestion. HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE: ACUTE INHALATION..............: The potassium sulfite, hydroquinone and potassium carbonate in this product are expected to be irritating to the respiratory tract with symptoms of coughing, sore throat, and runny nose. Potassium sulfite may cause an allergic reaction in some asthmatics and sulfite sensitive individuals. Possible symptoms include bronchoconstriction, sweating, flushing, hives, rapid heart rate, decreased blood pressure, and anaphylaxis. Inhalation of diethylene glycol vapors is unlikely due to its low vapor pressure. However, if misted or handled atelevated temperatures, high concentrations of diethylene glycol can produce drowsiness, headache, dizziness, and nausea. CHRONIC INHALATION............: Persons who have been previously sensitized to sulfites should take precautions to prevent the inhalation of potassium sulfite. ACUTE SKIN CONTACT............: Potassium sulfite and hydroquinone can be irritating to the skin with symptoms of reddening, itching, and swelling. Potassium carbonate can be severely irritating with symptoms of reddening, itching, swelling, and possible burns. Hydroquinone may cause skin sensitization with symptoms of rash, itching, hives, and swelling. CHRONIC SKIN CONTACT..........: Sensitization with dermatitis or hives may occur. ACUTE EYE CONTACT.............: Potassium sulfite and hydroquinone can be irritating to the eyes with symptoms of tearing, stinging, reddening, and swelling. Potassium carbonate can be severely irritating with possible burns. CHRONIC EYE CONTACT...........: Repeated exposure to hydroquinone may cause intolerance of the eyes to light. In addition, repeated overexposure to hydroquinone may cause pigment deposition, which can extend into the cornea with continued exposure to high concentrations. This pigment deposition does not impair vision. ACUTE INGESTION...............: Ingestion of this product may cause gastrointestinal irritation. Ingestion of diethylene glycol can result in behavioral change, drowsiness, kidney and liver failure, and coma. The oral toxicity of diethylene glycol is greater in humans than in laboratory animals. The estimated single lethal dose-oral-human is 1.0 ml/kg. Hydroquinone may be harmful if swallowed with symptoms including nausea, vomiting, drowsiness, dizziness, disorientation, bluish skin color, and stomach pain. CHRONIC INGESTION.............: None known. OTHER EFFECTS OF EXPOSURE.....: See Section 11. CARCINOGENICITY...............: The components of this product are not listed by NTP, IARC or regulated as a carcinogen by OSHA. MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE......: Persons with preexisting eye, skin, liver, or kidney conditions or impaired pulmonary function may be more susceptible to the effects of this product.